| 林弘睿,万乃君,钱 艺,张亚妹,张 骞.小儿肺热咳喘口服液联合阿奇霉素对肺炎支原体肺炎患儿肺功能和炎性因子的影响[J].现代生物医学进展英文版,2019,19(17):3267-3270. |
| 小儿肺热咳喘口服液联合阿奇霉素对肺炎支原体肺炎患儿肺功能和炎性因子的影响 |
| Effects of Xiaoer Feire Kechuan oral Liquid Combined with Azithromycin on Pulmonary Function and Inflammatory Factors in Children with Mycoplasma Pneumonia |
| Received:April 04, 2019 Revised:April 27, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.17.013 |
| 中文关键词: 小儿肺热咳喘口服液 阿奇霉素 肺炎支原体肺炎 肺功能 炎性因子 |
| 英文关键词: Xiaoer Feire Kechuan oral liquid Azithromycin Mycoplasma pneumoniae pneumonia Pulmonary function Inflammatory factors |
| 基金项目:北京市医院管理局儿科学科协同发展中心儿科专项重点项目（XTZD20180401） |
| Author Name | Affiliation | E-mail | | LIN Hong-rui | Department of Pediatrics, Beijing Jishuitan Hospital, Beijing, 100035, China | lin84123@sohu.com | | WAN Nai-jun | Department of Pediatrics, Beijing Jishuitan Hospital, Beijing, 100035, China | | | QIAN Yi | Department of Pediatrics, Beijing Jishuitan Hospital, Beijing, 100035, China | | | ZHANG Ya-mei | Department of Pediatrics, Beijing Jishuitan Hospital, Beijing, 100035, China | | | ZHANG Qian | Department of Pediatrics, Beijing Jishuitan Hospital, Beijing, 100035, China | |
|
| Hits: 1097 |
| Download times: 820 |
| 中文摘要: |
| 摘要 目的：探讨小儿肺热咳喘口服液联合阿奇霉素对肺炎支原体肺炎患儿肺功能和炎性因子的影响。方法：选取2016年1月~2017年12月期间我院收治的175例肺炎支原体肺炎患儿，根据随机数字表法将其分为对照组（n=87，阿奇霉素治疗）和研究组（n=88，小儿肺热咳喘口服液联合阿奇霉素治疗），比较两组患儿临床疗效、临床症状消失时间、肺功能指标[第1s用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC]、炎性因子指标[肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、C反应蛋白（CRP）]，记录两组患儿不良反应发生情况。结果：研究组患儿治疗后临床总有效率为94.32%（83/88），高于对照组患儿的80.46%（70/87）（P<0.05）。研究组患儿咳嗽、发热、湿啰音、哮鸣音的消失时间均短于对照组（P<0.05）。两组患儿治疗后FEV1、FVC、FEV1/FVC均升高，且研究组高于对照组（P<0.05）。两组患儿治疗后IL-6、CRP、TNF-α水平均降低，且研究组低于对照组（P<0.05）。两组患儿不良反应发生率对比无统计学差异（P>0.05）。结论：小儿肺热咳喘口服液联合阿奇霉素治疗肺炎支原体肺炎患儿的疗效优于单用阿奇霉素，且可有效改善患儿肺功能和炎性因子水平，快速缓解临床症状，促进患儿恢复。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Xiaoer Feire Kechuan oral liquid combined with azithromycin on pulmonary function and inflammatory factors in children with mycoplasma pneumoniae pneumonia. Methods: 175 children with mycoplasma pneumoniae pneumonia who were admitted to our hospital from January 2016 to December 2017 were selected, and they were divided into control group (n=87, azithromycin treatment) and study group (n=88, Xiaoer Feire Kechuan oral liquid combined with azithromycin treatment) according to random number table method. The clinical efficacy, disappearance time of clinical symptoms and pulmonary function indexes [forced expiratory volume in 1st second (FEV1), forced vital capacity (FVC), FEV1/FVC], inflammatory factor indexes [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP)] of the two groups were compared, and the occurrence of adverse reactions in two groups of children were recorded. Results: The total clinical effective rate of the study group was 94.32% (83/88), which was higher than 80.46% (70/87) of the control group(P<0.05). The disappearance time of cough, fever, moist rale and wheezing in the study group were shorter than those in the control group(P<0.05). The FEV1, FVC and FEV1/FVC in both groups after treatment increased, and the levels in the study group were higher than those in the control group(P<0.05). The levels of IL-6, CRP and TNF-α in both groups after treatment decreased, the levels of the study group were lower than those in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: The curative effect of Xiaoer Feire Kechuan oral liquid combined with azithromycin in treating children with mycoplasma pneumonia is better than that of azithromycin alone. It can effectively improve the pulmonary function and inflammatory factor level of children, quickly relieve clinical symptoms, and promote the recovery of children. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
